BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...
Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the “Company”), a ...
Genetic markers, specifically tumor necrosis factor alpha receptor 2 (TNFR2) gene polymorphisms, may predict response to TNF inhibitor therapy in patients with rheumatoid arthritis (RA). This approach ...
TNF Pharmaceuticals (TNFA) announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha inhibitor drug isomyosamine as a treatment for ...
PsyPost on MSN
Neuroscientists link a common inflammatory molecule to the dopaminergic mechanisms of addiction
A new study published in the journal Science Signaling has found that an immune system protein plays a central role in the addictive mechanisms of methamphetamine. The findings suggest that tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results